Early results from a biomarker-directed phase 2 trial of SY-1425 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) demonstrate DHRS3 induction and myeloid differentiation following Sy-1425 treatment Meeting Abstract

  

Authors:	Jurcic, J. G.; Raza, A.; Vlad, G.; Stein, E. M.; Roshal, M.; Bixby, D. L.; Boyer, D. F.; Vigil, C. E.; Syrbu, S.; Sekeres, M. A.; Rogers, H. J.; Rizzieri, D. A.; Lagoo, A. S.; Roboz, G. J.; Redner, R. L.; Steensma, D. P.; Cook, R. J.; Moyo, T.; McKeown, M.; Waters, N. J.; Stephens, K.; Volkert, A.; Di Tomaso, E.; Roth, D. A.; Cortes, J. E.
Abstract Title:	Early results from a biomarker-directed phase 2 trial of SY-1425 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) demonstrate DHRS3 induction and myeloid differentiation following Sy-1425 treatment
Meeting Title:	59th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	130
Issue:	Suppl. 1
Meeting Dates:	2017 Dec 9-12
Meeting Location:	Atlanta, GA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2017-12-07
Language:	English
ACCESSION:	WOS:000432419406266
PROVIDER:	wos
DOI:	10.1182/blood.V130.Suppl_1.2633.2633
Notes:	Meeting Abstract: 2633 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/127081